Form 4: TScan Therapeutics CFO Jason Amello Acquires Stock Options
SEC Form 4 Filing
Jason Amello, CFO of TScan Therapeutics, acquired stock options for 270,000 shares at an exercise price of $3.065 on January 3, 2025.
Summary
- On February 11, 2025, a Form 4 filing was submitted to the SEC regarding Jason Amello, the Chief Financial Officer of TScan Therapeutics, Inc. (TCRX).
- The filing reports a transaction that occurred on January 3, 2025, where Amello acquired stock options for 270,000 shares of TScan Therapeutics.
- The exercise price for these options is $3.065 per share.
- The options vest over a four-year period, with 25% vesting on the one-year anniversary of the grant date (January 3, 2025), and the remaining balance vesting in equal monthly installments over the subsequent 36 months.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates alignment of the CFO's interests with shareholders through equity ownership.
Positives
- The acquisition of stock options by the CFO aligns his interests with those of the shareholders, potentially incentivizing him to improve the company's performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Option grants are a common form of executive compensation in the biotech industry.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- The vesting schedule of 25% after one year followed by monthly installments over three years is a typical vesting arrangement.
- The specific number of options granted and the exercise price would need to be compared to similar companies and executive roles to assess the competitiveness of the compensation package.
Stakeholder Impact
- Shareholders may view the option grant as a positive sign, aligning management's interests with their own.
- Employees may see the option grant as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of the stock option grant and transaction. |
| 01/03/2025 | First vesting date for 25% of the stock options. |
| 01/03/2035 | Expiration date of the stock options. |
| 02/11/2025 | Date the Form 4 was signed and submitted. |
Keywords
TScan Therapeutics, Jason Amello, stock options, Form 4, SEC, TCRX, CFO, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.